To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Samus Therapeutics company closure

Conditions

Alzheimer Disease

Interventions

RADIATION: Tau Positron emission tomography (PET)
RADIATION: Fluorodeoxyglucose (FDG) Positron emission tomography (PET)
DIAGNOSTIC_TEST: Cerebrospinal fluid (CSF) Biomarkers
DIAGNOSTIC_TEST: Blood Biomarkers
BEHAVIORAL: Rating Scales
DRUG: PU-AD
DRUG: Placebo

Sponsor

Samus Therapeutics, Inc.